Navigation Links
Insmed Announces First Quarter 2008 Financial Results

RICHMOND, Va., May 8 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics (FOB) and biopharmaceuticals, today reported results for the first quarter ended March 31, 2008.

Recent Company Highlights

-- Follow-on Biologics Program

-- Received regulatory approval from the United Kingdom's Medicines and

Healthcare products Regulatory Agency to initiate a clinical trial

for Insmed's most advanced FOB candidate, INS-19 (Granulocyte Colony

Stimulating Factor or G-CSF), a FOB of the FDA-approved product

Neupogen(R), which had U.S. sales of approximately $0.9 billion in


-- Received and completed questionnaire from the Chairman and Ranking

Member of the U.S. House of Representatives' Subcommittee on Health

on the possible development of legislation to establish a FOB

regulatory pathway and;

-- Participated in two FOB-focused events: the Center for Business

Intelligence's "Evaluate the Legislative, Economic and Scientific

Implications of the Industry Debate on: Biosimilars and Follow-On

Biologics", and the American Enterprise Institute Follow-On

Biologics Program.


-- All sites have been initiated, received Investigational Review Board

approvals and are actively recruiting trial participants in the

Phase 2 clinical trial for IPLEX(TM) in Myotonic Muscular Dystrophy

("MMD"). The trial presently has 50% of the required 60 patients

enrolled and:

-- Received $2.3 million in cost recovery revenue in the first quarter

related to the expanded access program ("EAP") for IPLEX(TM) in

Italy to treat patients with Amyotrophic Lateral Sclerosis ("ALS"),

also known as Lou Gehrig's Disease. The EAP currently includes 20

physicians and approximately 90 subjects have enrolled.

"We continue to be pleased with the progress achieved in both our FOB and IPLEX(TM) programs," said Geoff Allan, President and CEO of Insmed. "We are aggressively pursuing a partner for our FOB program and continue to advance the development of IPLEX(TM) in MMD and ALS."

Revenues for the first quarter ended March 31, 2008 were $2.3 million, up from $1.7 million for the corresponding period in 2007. The increase was primarily attributable to a $1.6 million improvement in cost recovery from our EAP to treat patients with ALS in Italy. This was partially offset by the revenues lost from our withdrawal of IPLEX(TM) in the short stature market pursuant to the terms of our March 2007 Settlement Agreement with Genentech Inc. and Tercica Inc., and the absence of license income from our agreement with Napo Pharmaceuticals Inc., ("Napo") from which we received a milestone payment in the first quarter of 2007.

The net loss for the first quarter of 2008 was $4.8 million or $0.04 per share, compared with a net loss of $10.3 million or $0.10 per share in the first quarter of 2007. This $5.5 million improvement was primarily attributable to the $0.6 million increase in revenues noted above and a $4.9 million reduction in total expenses.

The $4.9 million total reduction in expenses was due to a $3.9 million decline in selling, general and administrative expenses ("SG&A Expenses"), a $0.9 million decrease in research and development expenses ("R&D Expenses"), and the elimination of $576,000 cost of goods sold, which was partially offset by a $392,000 non-cash loss on investments.

The reduction in SG&A Expenses was due primarily to the elimination of litigation expenses following the March 2007 settlement and the removal of commercial expenses associated with our business restructuring plan. The elimination of the cost of goods sold resulted from our withdrawal of IPLEX(TM) from the short stature market. The lower R&D Expenses reflected the reduced operating costs at our manufacturing facility located in Boulder, Colorado as we streamlined the facility to support our clinical activities following the withdrawal of IPLEX(TM) from the commercial short stature market. The realized loss on investments arises from the write-down of our investment in Napo. This investment, which was funded by a milestone payment from Napo, was recorded as part of our agreement with Napo in 2007.

Interest income in the first quarter of 2008 at $279,000 was slightly below the $301,000 earned in the same period of 2007 and was primarily due to the lower interest rate environment. Interest expense increased to $354,000 in the most recent period from $151,000 during the corresponding period of 2007. The reduction was due to an increase in the debt discount amortization resulting from the quarterly payment of our 2005 convertible notes, which began in March 2008.

As of March 31, 2008, we had total cash, cash equivalents and short-term investments on hand of $12.0 million, compared to $16.5 million on hand as of December 31, 2007. The $4.5 million decrease in cash, cash equivalents and short-term investments primarily reflects the use of $3.9 million for operating activities and a $553,000 principal repayment of our 2005 convertible notes, which began on March 1, 2008.

Conference Call

To participate in today's 8:30 AM ET live conference call, please dial 888-680-0879 (U.S. callers) or 617-213-4856 (international callers), and provide passcode 36651483. A live webcast of the call will also be available at: Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days beginning today at 10:30 AM ET at 888-286-8010 (U.S. callers) or 617-801-6888 (international callers), using passcode 13315852.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:

Brian Ritchie - FD


Corporate Communications Contact:

John Procter - Gibraltar Associates



Consolidated Balance Sheets

(in thousands, except share and per share data)


March 31, December 31,

2008 2007


Current assets:

Cash, cash equivalents and short-term

investments $12,030 $16,479

Accounts receivable, net 327 250

Prepaid expenses 110 244

Total current assets 12,467 16,973

Long-term assets:

Restricted cash - long term 2,095 2,095

Investments 108 258

Deferred financing costs, net 142 170

Property and equipment, net - 4

Total long-term assets 2,345 2,527

Total assets $14,812 $19,500

Liabilities and stockholders' equity

Current liabilities:

Accounts payable $804 $904

Accrued project costs & other 515 503

Payroll liabilities 799 631

Interest payable 20 23

Deferred rent 115 115

Deferred income 271 245

Convertible debt 2,211 2,211

Debt discount (865) (950)

Net convertible debt 1,346 1,261

Total current liabilities 3,870 3,682

Long-term liabilities:

Convertible debt 2,211 2,764

Debt discount (476) (651)

Net long-term convertible debt 1,735 2,113

Asset retirement obligation 2,217 2,217

Total liabilities 7,822 8,012

Stockholders' equity:

Common stock; $.01 par value; authorized

shares 500,000,000; issued and outstanding

shares, 121,904,312 1,219 1,219

Additional paid-in capital 341,403 341,270

Accumulated deficit (335,632) (330,759)

Accumulated other comprehensive loss:

Unrealized loss on investment - (242)

Net stockholders' equity 6,990 11,488

Total liabilities and stockholders' equity $14,812 $19,500


Consolidated Statements of Operations

(in thousands, except per share data - unaudited)

Three Months Ended

March 31,

2008 2007

Sales, net $ - $423

Royalties 25 35

License income - 500

Other expanded access program income 2,292 702

Total revenues 2,317 1,660

Operating expenses:

Cost of goods sold - 576

Research and development 5,241 6,105

Selling, general and administrative 1,482 5,382

Realized loss on investments 392 -

Total expenses 7,115 12,063

Operating loss (4,798) (10,403)

Interest income 279 301

Interest expense (354) (151)

Net loss $(4,873) $(10,253)

Basic and diluted net loss per share $(0.04) $(0.10)

Shares used in computing basic and diluted

net loss per share 121,904 101,328


Consolidated Statements of Cash Flows

(in thousands - unaudited)

Three Months Ended

March 31,

2008 2007

Operating activities

Net loss $(4,873) $(10,253)

Adjustments to reconcile net loss to net cash

used in operating activities:

Depreciation and amortization 292 82

Stock based compensation expense 133 56

Stock options issued for services - 8

Changes in operating assets and liabilities:

Accounts receivable (77) 130

Inventory - 576

Other assets 134 52

Accounts payable (100) (2,936)

Accrued project costs 12 (547)

Payroll liabilities 168 812

Deferred income 26 -

Asset retirement obligation - 147

Interest payable (3) -

Net cash used in operating activities (4,288) (11,873)

Investing activities

Decreases (increases) of short-term investments 5,601 12,044

Purchases of investments - (500)

Realized loss on investments 392 -

Net cash provided by investing activities 5,993 11,544

Financing activities

Repayment of convertible notes (553) -

Cash restricted to restricted letters of credit - 297

Net cash (used in) provided by financing activities (553) 297

Increase (decrease) in cash and cash equivalents 1,152 (32)

Cash and cash equivalents at beginning of period 3,554 2,121

Cash and cash equivalents at end of period $4,706 $2,089

Supplemental information

Cash paid for interest $68 $71

The table below details the "Cash and cash equivalents" from the statement of cash flows to "Cash, cash equivalents and short-term investments" shown on the balance sheet.

March 31, December 31,

2008 2007

Cash and Cash Equivalents 4,706 3,554

Short-Term Investments 7,324 12,925

Total Cash and Cash Equivalents and

Short-Term Investments 12,030 16,479

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series ... 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population ... challenge of how to continue to feed a growing nation. At the same time, ...
(Date:10/9/2017)... ... 09, 2017 , ... The Giving Tree Wellness Center announces ... needs of consumers who are incorporating medical marijuana into their wellness and health ... As operators of two successful Valley dispensaries, The Giving Tree’s two founders, Lilach ...
(Date:10/7/2017)... ... October 06, 2017 , ... With ... microscopy and surface analysis, Nanoscience Instruments is now expanding into Analytical Services. ... range of contract analysis services for advanced applications. Services will leverage techniques ...
(Date:10/7/2017)... Oct. 6, 2017  The 2017 Nobel Prize ... scientists, Jacques Dubochet, Joachim Frank and ... cryo-electron microscopy (cryo-EM) have helped to ... structural biology community. The winners worked with systems ... routinely produce highly resolved, three-dimensional images of protein ...
Breaking Biology Technology:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):